Skip to main content
Eikon Therapeutics, Inc. (EIKN)
NASDAQ: EIKN · Real-Time Price · USD
5.98
-0.06 (-0.99%)
Nov 13, 2026, 4:00 PM EST - Market closed

Eikon Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23
Net Income
-337.13-324.25-243.81-242
Depreciation & Amortization
20.4824.1825.3917.75
Asset Writedown & Restructuring Costs
0.2121.23-35
Loss (Gain) From Sale of Investments
-2.11-5.54-9.46-21.11
Stock-Based Compensation
14.618.0412.439.54
Change in Accounts Payable
1.89-3.812.950.24
Change in Other Net Operating Assets
36.681.6577.79.74
Operating Cash Flow
-265.67-188.52-134.8-190.85
Operating Cash Flow Growth
----

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23
Capital Expenditures
-1-46.74-84.8-28.51
Investment in Securities
-90.14-134.6236.15165.46
Investing Cash Flow
-91.14-181.34151.35136.95

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23
Issuance of Common Stock
350.581.90.240.4
Financing Cash Flow
350.58352.050.24105.81

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23
Net Cash Flow
-6.23-17.8116.851.91

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23
Free Cash Flow
-266.67-235.26-219.6-219.36
Free Cash Flow Growth
----
Free Cash Flow Per Share
-7.34-81.29-87.16-108.26
Levered Free Cash Flow
-166.74-208.89-190.73-
Unlevered Free Cash Flow
-166.21-208.37-190.71-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23
Cash Interest Paid
0.020.890.030.04
Change in Working Capital
38.4977.8480.659.98
SEC Filings: 10-K · 10-Q